Option chain shows key data for Nutriband's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Nutriband.

Nutriband (NASDAQ:NTRBW) Stock, Option Chain

Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

Cannabis

News

Penny Stocks

Small Cap

Markets

BBBY

NTRB

NTRBW

URBN

Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), has signed an exclusive manufacturing agreement with Fleur Marché for its CBD and Botanical Patch lines.

Nutriband To Manufacture Fleur Marché-Branded CBD Wellness Patches

Nutriband Inc

HC Wainwright &amp; Co. analyst Arthur He downgrades LAVA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVTX#NASDAQ">LVTX</a>) from Buy to Neutral and lowers the price target from $2 to $1.5.

Downgrades

Price Target

Analyst Ratings

LVTX

HC Wainwright & Co. Downgrades LAVA Therapeutics to Neutral, Lowers Price Target to $1.5

WIIM

PDSB

PDS Biotechnology shares are trading lower after the company announced up to $22 million registered direct offering priced at-the-market under Nasdaq rules.

Piper Sandler analyst Arvind Ramnani maintains PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Neutral and lowers the price target from $85 to $76.

PYPL

Piper Sandler Maintains Neutral on PayPal Holdings, Lowers Price Target to $76

Piper Sandler analyst Arvind Ramnani maintains Lemonade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) with a Neutral and lowers the price target from $44 to $34.

LMND

Piper Sandler Maintains Neutral on Lemonade, Lowers Price Target to $34

Needham analyst Ryan MacDonald reiterates Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) from Hold to Hold.

Reiteration

TDOC

Needham Reiterates Hold on Teladoc Healthto Hold

New Jersey's latest budget proposal could shake up the <a href="https://www.benzinga.com/general/sports-betting">online sports betting (OSB)</a> <a href="https://www.benzinga.com/general/gaming">and iGaming landscape</a>. 
JPMorgan analyst Joseph Greff is ringing the alarm. Governor Phil Murphy's fiscal year 2026 budget plan includes a tax rate hike for OSB and iGaming operators, jumping to 25% from 13% and 15%, respectively.
While this isn't a done deal — last year's proposed increase to 30% failed — the governor's endorsement raises the odds of some form of tax bump passing this time.
Read Also: <a href="https://www.benzinga.com/general/entertainment/25/02/43495392/africas-1-8-billion-gaming-boom-why-microsoft-cant-ignore-mobile">Africa&#8217;s $1.8 Billion Gaming Boom: Why Microsoft Can&#8217;t Ignore Mobile</a>
<h2 class="wp-block-heading">DraftKings Feels The Heat</h2>
If implemented by July 2025, Greff estimates that DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) could take a $52 million to $57 million EBITDA hit next year. That's roughly 5% to 6% of its projected 2025 EBITDA midpoint of $950 million — no small change.
Investors may recall DraftKings already bracing for a $50 million hit in the second half of 2024 due to Illinois' tax hike. This latest proposal would add another hurdle for the sports betting giant.
<h2 class="wp-block-heading">Other Operators In The Crosshairs</h2>
It's not just DraftKings feeling the squeeze. 
BetMGM, a subsidiary of MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>), could see a $35 million to $39 million EBITDA impact.
On the other hand, Caesars Digital, a unit of Caesars Entertainment Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) and PENN Entertainment Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) Penn Interactive would take smaller, yet still noticeable, hits of $15 million to $16 million and $3 million to $4 million, respectively.
<h2 class="wp-block-heading">Investor Implications: Who Comes Out On Top?</h2>
While tax increases are never welcome news, Greff suggests that the biggest players — like DraftKings and BetMGM — are best positioned to weather the storm. Their scale and brand power provide some cushion against regulatory shifts.
Additionally, states looking to plug budget gaps could accelerate iGaming legislation, potentially creating new market opportunities. For investors, keeping an eye on legislative developments in New Jersey and beyond could be key to navigating the evolving regulatory landscape.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports-betting/25/02/43790659/draftkings-well-positioned-for-double-digit-revenue-growth-analysts-say">DraftKings &#8216;Well Positioned For Double-Digit Revenue Growth,&#8217; Analysts Say</a></li>
</ul>
Image: Shutterstock

Analyst Color

Gaming

Sports Betting

General

DKNG

PENN

New Jersey's Tax Hike Gambit: DraftKings, BetMGM Brace For Impact

SPRC

SciSparc Enters Agreement To Provide $2M Loan To AutoMax Motors

Universal Health Services shares are trading higher after the company reported better-than-expected Q4 financial results.

OCGN

Ocugen Reaches Alignment With FDA To Move Forward With Phase 2/3 Confirmatory Clinical Trial Of OCU410ST In Stargardt Disease

Fomento Economico (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMX#NYSE">FMX</a>) reported $10.381 billion in sales this quarter. This is a 4.08 percent decrease over sales of $10.822 billion the same period last year.

Earnings

Fomento Economico Mexicano S.A.B. De C.V.

Fomento Economico Q4 Net majority income  US$0.91 per FEMSA ADS , Total revenues US $10.381B Down From $10.822B YoY

Glauber Contessoto, also known as &#8216;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42097462/dogecoin-millionaire-shares-50-million-meme-coin-strategy-for-2025-pepe-brett-are-this-bull-runs-doge-shiba-inu">the Dogecoin millionaire</a>&#8216;, has listed his meme coin conviction plays pointing to the best one for the cycle.
What Happened: In an <a href="https://x.com/ProTheDoge/status/1894936861799276714">X</a> post on Thursday, Contessoto doubled down on his meme coin conviction plays, predicting Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), Floki Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">FLOKI</a>), Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>) and Brett (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BRETT</a>) will dominate this bull run, &#8220;leaving everyone else in the dust.&#8221;
He believes FLOKI stands out in marketing, citing its global advertising efforts over the past four years. 
Contessoto sees it as underrated and expects it to outperform many other meme coins when its time comes.
He stated that he has been bullish on FLOKI since 2021, reaffirming his belief it will go parabolic in 2025 as visibility increases. 
His strategy is to bet on established, community-driven, top 10 meme coins.
In another <a href="https://x.com/ProTheDoge/status/1894445972052136258">X</a> post, the millionaire trader noted the &#8220;unusual red February&#8221; in comparison to previously green Februaries, calling it "unprecedented times."
Crypto trader Shelby <a href="https://x.com/CryptoNewton/status/1894790888477315424">stated</a> his belief that the next top meme coin is not Dogecoin or Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) but Floki. 
He calls it a meme coin with real utility and global branding partnerships.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43945957/liquidity-is-disappearing-bitcoins-downturn-spells-doom-for-altcoins-analyst-warns">&#8216;Liquidity Is Disappearing&#8217;: Bitcoin&#8217;s Downturn Spells Doom For Altcoins, Analyst Warns</a>
What's Next: Crypto trader Jelle spotted a bullish divergence on the Floki chart, noting that momentum is picking up while the price is making lower lows.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Higher lows in the RSI, lower lows in price. Divergences like these tend to result in a bounce. Eyes on a reclaim of 10000.<a href="https://twitter.com/search?q=%24FLOKI&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$FLOKI</a> <a href="https://t.co/W4zF0Nu7YB">pic.twitter.com/W4zF0Nu7YB</a>
&mdash; Jelle (@CryptoJelleNL) <a href="https://twitter.com/CryptoJelleNL/status/1894748739689967652?ref_src=twsrc%5Etfw">February 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto chart analyst Ali Martinez <a href="https://x.com/ali_charts/status/1894918371734421887">highlighted</a> a buy signal on DOGE's daily chart as reflected in the TD Sequential indicator. He believes the chart is ready for a rebound.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43874379/dogecoin-millionaire-pushes-conviction-plays-like-pepe-like-theres-no-tomorrow-best-time-to-start-buying">Dogecoin &#8216;Millionaire&#8217; Pushes &#8216;Conviction Plays&#8217; Like PEPE Like There&#8217;s No Tomorrow: &#8216;Best Time To Start Buying&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BRETT

$DOGE

$FLOKI

$PEPE

$SHIB

'Dogecoin Millionaire' Shares Meme Coin Picks 'Leaving Everyone Else In The Dust': Did DOGE, SHIB, PEPE Make The Cut?

Telsey Advisory Group analyst Dana Telsey maintains Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) with a Outperform and maintains $43 price target.

BBWI

Telsey Advisory Group Maintains Outperform on Bath & Body Works, Maintains $43 Price Target

Stephens &amp; Co. analyst Jim Salera reiterates Papa John's International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PZZA#NASDAQ">PZZA</a>) with a Overweight and maintains $60 price target.

PZZA

Stephens & Co. Reiterates Overweight on Papa John's International, Maintains $60 Price Target

Piper Sandler analyst David Westenberg maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Overweight and raises the price target from $200 to $205.

Piper Sandler Maintains Overweight on Zoetis, Raises Price Target to $205

GreenSpark – Backed by BMW i Ventures and Gaining Significant Adoption in the Metal Recycling Sector – is Expected to Power $GWAV's Ambitious 2025 Growth Plans
<ul>
<li>Greenwave Supplies Industry Titans Nucor, Sims Metal, Cleveland-Cliffs, and Georgia-Pacific with 100% U.S.-Sourced Recycled Metals</li>
<li>$GWAV Recently Raised 2025 Revenue Outlook to $47-$50 Million, Signaling Robust Growth Resulting from President Trump's Steel and Aluminum Tariffs</li>
<li>GreenSpark's AI-Driven Platform is Focused on the Multi-Billion-Dollar Scrap Metal Industry</li>
</ul>

GWAV

Greenwave Technology Solutions Selects GreenSpark As Operating System For Operational Efficiency

Vistra Corp shares are trading higher. The company reported Q4 financial results.

Piper Sandler analyst Jessica Tassan maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Overweight and lowers the price target from $13 to $12.

Piper Sandler Maintains Overweight on Teladoc Health, Lowers Price Target to $12

The GEO Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) shares are trading lower after the company reported&nbsp;fourth-quarter revenue of&nbsp;$607.7&nbsp;million, beating <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b44000823/the-geo-group-reports-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">the&nbsp;consensus of&nbsp;$607.44 million</a>.
Adjusted EBITDA declined to&nbsp;$108.0&nbsp;million from&nbsp;$129.0&nbsp;million a year ago quarter. Adjusted EPS&nbsp;of&nbsp;13 cents came below&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the consensus of&nbsp;22 cents</a>.
Revenue for the fourth quarter of 2024 rose sequentially compared to the third quarter. However, earnings and adjusted EBITDA fell short of the company&#8217;s guidance, largely due to the elevated general and administrative expenses incurred during the period.
The increase in general and administrative expenses was partly due to previously announced management team reorganization and additional professional fees associated with preparing for future growth initiatives and related operations in 2025.
George C. Zoley, Executive Chairman of GEO, said, &#8220;In 2024, we also incurred $9 million of our previously announced $70 million investment to strengthen our capabilities to deliver expanded detention capacity, secure transportation, and electronic monitoring services to U.S. Immigration and Customs Enforcement (&#8220;ICE&#8221;) and the federal government.&#8221;
The company&#8217;s total net debt was approximately&nbsp;$1.7 billion at the end of the&nbsp;fourth quarter 2024.
Outlook: Geo sees FY25&nbsp;outlook for EPS of&nbsp;$0.74–&nbsp;$0.88 (vs. the consensus estimate of&nbsp;$1.55), adjusted EBITDA of $460 million-$485 million and revenue of around $2.5 billion <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">(vs. consensus of $2.76 billion)</a>.
In 2025, the company expects to further reduce the total net debt by around $150 million to $175 million, bringing the total net debt to about $1.55 billion.
In a separate release, Geo disclosed that it secured a 15-year, fixed-price contract worth about $1 billion with U.S. Immigration and Customs Enforcement (ICE) to provide support services for a federal immigration processing center at its 1,000-bed <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b44000864/the-geo-group-awarded-15-year-contract-by-u-s-immigration-and-customs-enforcement-for-company-owne" rel="noreferrer noopener">Delaney Hall Facility in Newark, New Jersey</a>.
The new support services contract is expected to generate over $60 million in annual revenue for GEO in its first full year, with margins in line with GEO&#8217;s Secure Services facilities.
GEO plans to reactivate the facility in the&nbsp;second quarter&nbsp;of 2025, with revenue and earnings normalizing in the second half of the year.
Investors can gain exposure to the stock via&nbsp;Ballast Small/Mid Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGMT#NYSE">MGMT</a>) and Schwab Fundamental U.S. Small Company ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNDA#NYSE">FNDA</a>).
Price Action: GEO shares are down 4% at $24.75 premarket at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/02/43483622/bukeles-big-house-el-salvador-offers-us-a-prison-deal-like-no-other-musk-says-great-idea" target="_blank" rel="noreferrer noopener">Bukele&#8217;s Big House: El Salvador Offers US A Prison Deal Like No Other, Musk Says &#8216;Great Idea&#8217;</a></li>
</ul>

Equities

Mid Cap

Guidance

Movers

FNDA

MGMT

GEO Q4 Earnings: Sales Beat, EPS Miss, New Immigration Contract And More

TSAT

Telesat shares are trading higher after the company announced a  partnership with Intellian for Ka-Band flat panel user terminals.

Applovin shares are trading higher. The stock may be moving up after the company CEO released a note addressing the short seller reports.

Press Releases

Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application

Legal

Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology

Nutriband Inc. to Present at The 2024 Noble Conference in Boca Raton on December 4th

Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025

Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology

Nutriband Issues Letter to Shareholders

Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™

Nutriband Inc. Announces Olympian Anastasia Nichita to Advisory Board

Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

Health Care

Nutriband Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development.

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Nutriband

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Nutriband

Nutriband (NTRBW) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga